FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know
On April 15, 2026, the FDA announced a significant regulatory update: injectable GHK-Cu (copper tripeptide-1) will be removed from the Category 2 bulk substances list by July 2026. This change affects compounding pharmacies, clinicians, and anyone researching this copper peptide — and it's been a long time coming.
What Is GHK-Cu?
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. Your body produces it — but levels decline significantly with age. At 20 years old, plasma concentrations run around 200 ng/mL. By 60, they've dropped to roughly 80 ng/mL.
This age-related decline has attracted serious scientific interest. GHK-Cu has been studied for its role in:
- Wound healing and tissue repair — it activates genes involved in collagen synthesis and extracellular matrix remodeling
- Skin regeneration — one of the most studied anti-aging peptides in dermatology; multiple human trials show meaningful improvements in fine lines, skin density, and wound closure rates
- Gene expression regulation — a landmark 2012 study found GHK-Cu upregulated over 4,000 genes associated with tissue repair and downregulated genes linked to inflammation and cancer progression
- Neuroprotection — early research suggests potential in protecting neurons from oxidative stress
It's not a fringe compound. GHK-Cu has been in the scientific literature for decades, and its safety profile in topical applications is well-established.
What Is Category 2 and Why Did It Matter?
The FDA's bulk substances framework for 503B outsourcing facilities categorizes compounds based on clinical need and risk. Category 2 substances are those placed on a "do not compound" restricted list — meaning compounding pharmacies cannot legally produce or sell them in injectable form.
GHK-Cu was placed in Category 2 in 2023 alongside several other peptides including BPC-157, TB-500, and MOTS-c. That decision drew criticism from researchers and clinician groups who argued the restrictions weren't supported by clinical evidence of harm — particularly for a peptide the human body already produces naturally.
The effect was practical and immediate: licensed compounding pharmacies could no longer prepare injectable GHK-Cu, pushing demand toward gray-market sources with zero quality control.
What the April 2026 Announcement Changes
The FDA's April 15 announcement signals that injectable GHK-Cu will be removed from the Category 2 list, with formal implementation expected in July 2026 when the FDA's peptide advisory panel is scheduled to reconvene and finalize updated guidance.
Once removed from Category 2, licensed 503B outsourcing facilities and 503A compounding pharmacies (with a valid patient-specific prescription) will again be permitted to compound injectable GHK-Cu under proper pharmaceutical standards.
What this means in practice:
- Compounding pharmacies that halted GHK-Cu production in 2023 can begin preparing to restock (once July guidance is finalized)
- Clinicians prescribing peptide protocols will have legitimate, pharmaceutical-grade sourcing options again
- Patients who've been sourcing from unregulated channels will have access to properly tested product
- Quality and safety will improve — compounded products from licensed facilities must meet USP standards for purity and sterility
What This Doesn't Mean
This is not FDA approval. GHK-Cu will not become a commercially approved drug overnight. It remains a compound that requires a prescription and access through a licensed compounding pharmacy. Off-label peptide protocols still exist in a complex legal and medical gray zone — proper physician oversight matters.
It also doesn't mean the research questions are settled. While GHK-Cu has a strong safety record and compelling mechanistic data, most of the clinical evidence remains in the early-to-moderate phase. Long-term human RCTs for systemic injectable use are limited.
And critically: the July 2026 advisory panel will also review BPC-157 and MOTS-c, two other peptides still under Category 2 restrictions. The outcomes for those compounds are still uncertain.